Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $5 price target.
Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $5 price target.